Загрузка...
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
BACKGROUND: The respiratory syncytial virus (RSV) fusion glycoprotein (F) is a molecule that fuses the viral and host cell membranes during virus entry as it rearranges from a meta-stable prefusion to a stable postfusion conformation. Using structure-guided design, Pfizer engineered a prefusion RSV...
Сохранить в:
| Опубликовано в: : | Open Forum Infect Dis |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809502/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2432 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|